Saundra L.  Pelletier net worth and biography

Saundra Pelletier Biography and Net Worth

Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led Evofem’s transition to the public market in January 2018 (NASDAQ: EVFM).

Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women’s healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised over $440 million.

In her more than 25 years of experience in the pharmaceutical industry, Ms. Pelletier has launched pharmaceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her experience includes a comprehensive range of women’s healthcare products, cardiovascular, pain management, sleep therapies and medical devices. She has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development and Strategic Partnerships.

Previously, Ms. Pelletier served as Vice President, Pharmaceuticals at Women First Healthcare, where she raised $40 million in capital. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit, managed worldwide partnerships, negotiated cost saving licensing agreements, assessed country infrastructures, developed commercialization plans and hired full scale teams, including contract sales forces.

In March 2020, she joined the Board of Directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer.  She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee. She is also a published author, coveted keynote speaker and moderator at key healthcare and political conferences worldwide.

She has appeared at the Harvard School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the MAKERS Conference, Women Deliver, the University of Virginia’s Darden School of Business, the University of Oregon’s Lundquist School of Business and the University of California, San Diego.

She is a trained Climate Reality Advocate and hosted a roundtable session at the International Conference on Climate Change, held in Reykjavik, Iceland. Ms. Pelletier has been profiled by The New York Times, Inc. Magazine, Cosmopolitan, Bustle, CNN, Glamour, Marie Claire, and Vogue. She was named as a New Champion for Reproductive Health by the United Nations Foundation, awarded the Athena San Diego’s Pinnacle Award for Life Sciences, named 2019 Business Woman of the Year by the San Diego Business Journal, and named to Inc. Magazine’s 2020 Female Founders 100 List.

What is Saundra L. Pelletier's net worth?

The estimated net worth of Saundra L. Pelletier is at least $17.79 as of May 27th, 2022. Ms. Pelletier owns 1,893 shares of Evofem Biosciences stock worth more than $18 as of December 23rd. This net worth approximation does not reflect any other assets that Ms. Pelletier may own. Additionally, Ms. Pelletier receives a salary of $1,520,000.00 as CEO at Evofem Biosciences. Learn More about Saundra L. Pelletier's net worth.

How old is Saundra L. Pelletier?

Ms. Pelletier is currently 54 years old. There are 1 older executives and no younger executives at Evofem Biosciences. Learn More on Saundra L. Pelletier's age.

What is Saundra L. Pelletier's salary?

As the CEO of Evofem Biosciences, Inc., Ms. Pelletier earns $1,520,000.00 per year. Learn More on Saundra L. Pelletier's salary.

How do I contact Saundra L. Pelletier?

The corporate mailing address for Ms. Pelletier and other Evofem Biosciences executives is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. Evofem Biosciences can also be reached via phone at (858) 550-1900 and via email at [email protected]. Learn More on Saundra L. Pelletier's contact information.

Has Saundra L. Pelletier been buying or selling shares of Evofem Biosciences?

Saundra L. Pelletier has not been actively trading shares of Evofem Biosciences during the last ninety days. Most recently, on Friday, May 27th, Saundra L. Pelletier bought 1,128 shares of Evofem Biosciences stock. The stock was acquired at an average cost of $43.75 per share, with a total value of $49,350.00. Following the completion of the transaction, the chief executive officer now directly owns 1,893 shares of the company's stock, valued at $82,818.75. Learn More on Saundra L. Pelletier's trading history.

Who are Evofem Biosciences' active insiders?

Evofem Biosciences' insider roster includes Russell Barrans (Insider), Justin File (CFO), Alexander Fitzpatrick (General Counsel), Kim Kamdar (Director), Anthony O'Brien (Director), Saundra Pelletier (CEO), and Lisa Rarick (Director). Learn More on Evofem Biosciences' active insiders.

Saundra L. Pelletier Insider Trading History at Evofem Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2022Buy1,128$43.75$49,350.001,893View SEC Filing Icon  
12/20/2021Buy1,080$47.50$51,300.00View SEC Filing Icon  
6/10/2021Buy400$128.75$51,500.006,806View SEC Filing Icon  
9/8/2020Sell980$407.50$399,350.00View SEC Filing Icon  
1/13/2020Sell26$750.00$19,500.002,898View SEC Filing Icon  
1/2/2020Sell53$756.25$40,081.252,924View SEC Filing Icon  
12/2/2019Sell160$912.50$146,000.002,978View SEC Filing Icon  
11/21/2019Sell80$751.25$60,100.003,397View SEC Filing Icon  
8/10/2018Buy80$263.75$21,100.00View SEC Filing Icon  
See Full Table

Saundra L. Pelletier Buying and Selling Activity at Evofem Biosciences

This chart shows Saundra L Pelletier's buying and selling at Evofem Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Evofem Biosciences Company Overview

Evofem Biosciences logo
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.01
Low: $0.01
High: $0.01

2 Week Range

Now: $0.01
Low: $0.01
High: $0.08

Volume

837,175 shs

Average Volume

916,706 shs

Market Capitalization

$1.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A